XOMA Corporation (NASDAQ: XOMA) is on The StockGuru Leader Board today. The stock is up as much as 27.52% on Tuesday.
Volume traded – so far – as this release was issued intraday: 8,602,140
Join in on the Discussion about XOMA: http://members.stockguru.com/stocks/xoma/
About the Company:
XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. Its products under development include gevokizumab, an anti-inflammatory monoclonal antibody that inhibits interleukin-1 beta and has completed Phase 2 development stage for the treatment of Behcets uveitis, as well as is in Phase 2b clinical trail for Type 2 diabetes with cardiovascular biomarkers; XOMA 3AB, a biodefense anti-botulism product candidate comprising a combination or cocktail of antibodies for the treatment of botulism poisoning; and preclinical antibody discovery programs in various indications, including autoimmune, cardio-metabolic, inflammatory, and oncological diseases. The company, through its collaboration agreement with Novartis AG, is also developing HCD122, a human anti-CD40 antagonist antibody that is in Phase 1/2 clinical trial for the treatment of B-cell mediated diseases, including malignancies and autoimmune diseases; and LFA102, which is in Phase 2 clinical trial for the treatment of hematologic tumors and other undisclosed diseases. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; SRI International; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; Genentech, Inc.; and UCB Celltech. XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California.
About the StockGuru Leader Board:
We watch for stocks moving up and creating a positive momentum in the market. We are not compensated for coverage.
Feel free to suggest a stock for coverage if you see it breaking out. Contact: [email protected].
StockGuru.com
StockGuruCanada.com
Shareholdervision.com
BoldStocks.com
IR Affiliates – IRIR.co
StoneBridge Web & SEO – StonebridgeIQ.com
All content on StockGuru.com is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: [email protected] or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070